IQ-AI Limited IQ-AI Announces Positive Interim Phase 1 Results (7354V)
05 December 2023 - 9:58PM
UK Regulatory
TIDMIQAI
RNS Number : 7354V
IQ-AI Limited
05 December 2023
IQ-AI Ltd
("IQ-AI" or the "Company")
IQ-AI Announces Positive Interim Phase 1 Results
On-going trial to study the safety of oral gallium maltolate in
relapsed GBM patients
-- All three planned dose levels tested to date continue to
exhibit favorable safety and tolerability
-- Patients report no adverse effects, side effects, or symptoms
-- An amendment to the study protocol is approved for dose escalation
Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI
Ltd (LSE: IQAI), is pleased to update shareholders with additional
positive details on the on-going study of oral gallium maltolate,
an investigational monotherapy for the treatment of
recurrent/refractory glioblastoma (GBM). These preliminary results
were recently presented by the study PI, Dr. Jennifer Connelly, MD,
at the Society for Neuro-Oncology (SNO) 28th Annual Meeting held
November 15-19 in Vancouver.
Seventeen patients have met the eligibility criteria and have
enrolled in the phase 1 component of the study. As of 30 November
2023, of the fourteen patients evaluable for treatment with oral
GaM, three patients have achieved a median progression-free
survival (PFS) of greater than 180 days, with 1 patient on
treatment for greater than one year. This compares favorably with
the 1.5 to 6-month range historically reported for progression-free
survival in this population of relapsed GBM.
Patients enrolled in the study have all received prior
treatments with some experiencing multiple episodes of cancer
recurrence. Historically, following GBM recurrence, patients have a
median overall survival (OS) of 2-9 months.
"We are encouraged by the favorable safety and tolerability
profile at all dose levels," said Dr. Christopher Chitambar, MD,
Chair of the study. "Other pre-clinical studies have been conducted
that demonstrate that oral gallium maltolate may prove to be a
viable treatment alternative across multiple solid tumors as
well."
"This is an encouraging update and I am pleased with the steady
progress being made by the team" said Trevor Brown, CEO of
IQ-AI.
--ENDS -
The Directors of the Company accept responsibility for the
contents of this announcement.
For further information, please contact:
IQ-AI Ltd
Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda
Tel: 020 7469 0930
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
About Imaging Biometrics(R) LLC : IB is a wholly owned
subsidiary of IQ-AI Limited, (LON: IQAI), and focuses on delivering
quantitative imaging platforms and therapeutics that transform how
clinicians diagnose and treat patients more efficiently and
effectively. For more information about Imaging Biometrics, visit
the company's website at www.imagingbiometrics.com . Follow IB on
Twitter, @IQAI_IB.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
STRUVORROOUURAA
(END) Dow Jones Newswires
December 05, 2023 05:58 ET (10:58 GMT)
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Dec 2024 to Jan 2025
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Jan 2024 to Jan 2025